Hong Kong
· Delayed Price · Currency is HKD Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Company Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China.
It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers.
The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.
In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis.
Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software.
It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects.
The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
| Country | China |
| Founded | 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 948 |
| CEO | Da Jun Zhao |
Contact Details
Address: Zhangjiang Hi-Tech Park Shanghai, 201210 China | |
| Phone | 86 21 5895 3355 |
| Website | fd-zj.com |
Stock Details
| Ticker Symbol | 1349 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000000W4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Da Jun Zhao | Co-Founder, GM and Chairman |
| Xue Yan ACCA, CIA, CICPA, FCCA, HKICPA | Chief Financial Officer, Deputy GM, Company Secretary and Director |
| Jun Li | Co-Founder and Deputy GM |
| Luo Chun Wang | Core Technical Personnel |
| Dai Qing Yu | Deputy General Manager |
| Yu Chen | Deputy General Manager |
| Xiaowen Li | Deputy General Manager |